To select the list of the world's most influential businesses of the year, TIME editors requested nominations across sectors, surveyed its global network of contributors and correspondents around the world, and sought advice from outside experts. They evaluated each company on key factors, including impact, innovation, ambition, and success. The result is a diverse group of organizations shaping the future of business and society. About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Thera ...

导读： 水木未来中标湖南师范大学冷冻电镜采购项目，成交金额1985万元，采购品为物电院高性能冷冻透射电子显微镜。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 6月16日， 水木未来 （北京）科技有限公司 成功中标 湖南师范大学 超长期国债第12批（物电院高性能冷冻透射电子显微镜） 单 一 来 源采购项目发布公告， 成 交金额 1985万元 ，中标品目为A02100301-显微镜。 该项目于2024年12月16日发布 采购意向公示 ，以单一来源采购形式，2000万元采购水木科仪（北京）科技 有限公司300kV冷冻透 射电镜。 水 木 未 来 （ 北 京 ） 科 技 有 限 公 司 拥 有 全 球 最 大 的 商 用 高 端 冷 冻 电 镜 平 台 ， 截 至 2023 年 共 有 9 台 高 配 电 镜 ， 其 中 8 台 为 300kV ， 1 台 为 120kV。水木科仪（北京）科技有限公司是水木未来全资子公司，主要承担水木未来在高端智能化科研仪器包括全系列冷冻电镜国产替 代板块的研发、生产和销售职能。 水木科仪（北京）科技有限公司是 ...

ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair’s 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 11:20 a.m. CT Goldman Sachs’ 46th Annual Global Healthcare ConferenceDate: Monday, June 9 ...

Summary of Merus Investor Call Company Overview - Merus is an oncology-focused company with a proprietary technology platform for developing bispecific and multispecific antibodies, including pitocentimab and other clinical assets [6][8][35] - The company received its first FDA approval for BIZENGRI, validating its capabilities in oncology drug development [6] Clinical Data Presentation - The call focused on the phase two interim clinical data of pitocentimab in combination with pembrolizumab for first-line recurrent metastatic head and neck squamous cell carcinoma [2][5] - Data will be presented at the ASCO Annual Meeting on June 2, 2025 [2][5] Key Clinical Findings - **Efficacy of Pitocentimab**: - The overall response rate (ORR) for pitocentimab monotherapy was 36% with a median duration of response of 6.2 months [17] - In combination with pembrolizumab, the ORR was 63% (27 out of 43 patients) with a 95% confidence interval indicating a lower bound of 49% [27] - The median progression-free survival (PFS) was 9 months, significantly higher than historical data for pembrolizumab alone [29] - The 12-month overall survival (OS) rate was 79%, compared to 51% for pembrolizumab monotherapy [30] - **Safety Profile**: - The combination therapy was well tolerated with no significant overlapping toxicities observed [32][26] - The incidence of treatment-emerging adverse events was manageable, with 38% of patients reporting infusion-related reactions [26] Market Opportunity - The head and neck cancer market is estimated to be around $4 billion in 2024, with significant unmet medical needs [37][39] - Merus aims to position pitocentimab as a first and best-in-class treatment option, potentially changing clinical practice [38][39] Regulatory and Development Strategy - Merus is confident in the potential for accelerated approval based on strong ORR and survival data [66] - The company plans to substantially enroll both Phase III registration trials by the end of 2025, with top-line readouts expected in 2026 [42][34] Intellectual Property - Merus holds a robust patent estate covering its platform technologies and clinical assets, ensuring protection for its innovations [35] Additional Insights - The company emphasizes the importance of including both HPV positive and negative patients in clinical trials, with a focus on maintaining a consistent patient population across studies [101][102] - There is a strong belief that the combination of pitocentimab and pembrolizumab could provide a transformative treatment option for patients with recurrent metastatic head and neck cancer [41][42] Conclusion - Merus is advancing its clinical development of pitocentimab with promising efficacy and safety data, aiming to address significant unmet needs in the oncology market, particularly in head and neck cancer [41][43]

Core Insights - Ansys has announced thermal and multiphysics signoff tool certifications for designs using Intel's 18A process technology, enhancing the reliability of advanced semiconductor systems for AI, GPUs, and HPC applications [2][8] - The collaboration between Ansys and Intel Foundry includes a comprehensive multiphysics signoff analysis flow for Intel's EMIB technology, facilitating the development of multi-die 3D integrated circuit systems [2][4] Group 1: Certification and Tools - Ansys RedHawk-SC and Totem are recognized for their speed, accuracy, and capacity in analyzing power integrity and reliability of Intel's 18A RibbonFET GAA transistors with PowerVia backside power delivery [3][8] - HFSS-IC Pro, a new addition to the HFSS-IC product family, is introduced for scalable electromagnetic analysis, certified for on-chip electromagnetic integrity in various telecommunication applications [3][8] - The qualification process for RedHawk-SC, Totem, and HFSS-IC Pro is ongoing for the Intel 18A high-performance process node, with customers able to request the latest Intel PDK for early design work [5][8] Group 2: Collaboration and Ecosystem - Ansys is joining the Intel Foundry Chiplet Alliance to develop a secure ecosystem for designing and manufacturing interoperable chiplets, enhancing multi-die assembly efficiency [6][7] - The collaboration aims to advance chiplet technology and improve the performance and integration of advanced computing systems through the EMIB-T technology, which will include through-silicon vias [4][7] - Ansys emphasizes the importance of precise tools for ensuring reliability in semiconductor systems, reinforcing its commitment to providing open-source and interoperable technology [7][8]